Patient Cures Spur Demand for $1,000 Hepatitis C Pill

The powerful new hepatitis C drug that sent Gilead Sciences Inc.’s sales soaring last quarter is doing the same for the hopes of millions of patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.